| Dr Christopher John Rott, DO | |
|
712 S Cascade St, Fergus Falls, MN 56537-2913 | |
| (218) 736-8000 | |
| (218) 739-6718 |
| Full Name | Dr Christopher John Rott |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 17 Years |
| Location | 712 S Cascade St, Fergus Falls, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114112539 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 56414 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lake Region Healthcare Corporation | Fergus falls, MN | Hospital |
| Prairie Ridge Hospital And Health Services | Elbow lake, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lake Region Healthcare Corporation | 3971565334 | 109 |
News Archive
Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.
More than 20 percent of U.S. adults receive periodic health examinations (PHE) each year, yet new research shows that patients who have an annual routine visit to their doctor may not receive recommended preventive screening tests and counseling services that could benefit their health.
Lung cancer is the number 1 killer among cancers, especially when it is of the non-small cell type. Among these, adenocarcinomas are the most common and aggressive type. These tumors also show a strong tendency to show dedifferentiation, or loss of the features that characterize a mature lung cell.
The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.
Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.
› Verified 7 days ago
| Entity Name | Prairie Ridge Hospital And Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407838329 PECOS PAC ID: 0648222349 Enrollment ID: O20050210000490 |
News Archive
Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.
More than 20 percent of U.S. adults receive periodic health examinations (PHE) each year, yet new research shows that patients who have an annual routine visit to their doctor may not receive recommended preventive screening tests and counseling services that could benefit their health.
Lung cancer is the number 1 killer among cancers, especially when it is of the non-small cell type. Among these, adenocarcinomas are the most common and aggressive type. These tumors also show a strong tendency to show dedifferentiation, or loss of the features that characterize a mature lung cell.
The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.
Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.
› Verified 7 days ago
| Entity Name | Lake Region Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093713372 PECOS PAC ID: 3971565334 Enrollment ID: O20060109000246 |
News Archive
Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.
More than 20 percent of U.S. adults receive periodic health examinations (PHE) each year, yet new research shows that patients who have an annual routine visit to their doctor may not receive recommended preventive screening tests and counseling services that could benefit their health.
Lung cancer is the number 1 killer among cancers, especially when it is of the non-small cell type. Among these, adenocarcinomas are the most common and aggressive type. These tumors also show a strong tendency to show dedifferentiation, or loss of the features that characterize a mature lung cell.
The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.
Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher John Rott, DO 712 S Cascade St, Fergus Falls, MN 56537-2913 Ph: (218) 736-8000 | Dr Christopher John Rott, DO 712 S Cascade St, Fergus Falls, MN 56537-2913 Ph: (218) 736-8000 |
News Archive
Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.
More than 20 percent of U.S. adults receive periodic health examinations (PHE) each year, yet new research shows that patients who have an annual routine visit to their doctor may not receive recommended preventive screening tests and counseling services that could benefit their health.
Lung cancer is the number 1 killer among cancers, especially when it is of the non-small cell type. Among these, adenocarcinomas are the most common and aggressive type. These tumors also show a strong tendency to show dedifferentiation, or loss of the features that characterize a mature lung cell.
The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.
Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.
› Verified 7 days ago
Julianne D Gutzmer, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 712 South Cascade Street, Fergus Falls, MN 56537 Phone: 218-736-8000 Fax: 218-736-8757 | |
Dr. Jeffrey A Horak, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 712 South Cascade Street, Fergus Falls, MN 56537 Phone: 218-736-8000 Fax: 218-736-8757 | |
James R Haeberlin, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 615 S Mill St, Fergus Falls, MN 56537 Phone: 218-739-2221 Fax: 218-739-5501 |